A pill that could treat post-traumatic stress disorder (PTSD) has shown promise in animal trials.

Current treatments for the condition, which affects one in 11 Americans, include electronic brain stimulation and potentially even using hallucinogens.

But biotechnology company Neurovation Labs is hoping to develop the first drug for the condition.

The pill will be less invasive than these types of treatments and may be easier to access for many.

The New York City-based firm has received funding from the U.S. Army and Air Force, and the military branches hope to develop stronger treatments for the condition that affects more than one out of every ten service members.

More